Forbion

Qur heartfelt congratulations to Forbion Operating Partner Professor John Kastelein, on achieving an exceptional milestone in his academic career. This remarkable achievement places Professor Kastelein among the top 1,000 scientists globally in terms of research impact. At Forbion we are privileged to benefit from his expertise. Congratulations once again, Professor Kastelein on this well-deserved recognition! #Forbion #KOL #scientist #lifesciences #biotech #research #expert

Forbion portfolio company Kynexis, a clinical-stage biotechnology company focused on precision therapeutics by leveraging biomarkers and human genetics for brain diseases, announced today the formation of its distinguished Scientific Advisory Board (SAB). Read more using the following link: https://lnkd.in/eRPSFBqz #scientificboard #expertise #lifesciences #biotech Dr. Dmitrij Hristodorov Tim Lohoff, Ph.D.

Forbion is thrilled to announce that its portfolio company, Numab Therapeutics AG has entered into a definitive agreement with Johnson & Johnson (JNJ) to acquire Yellow Jersey Therapeutics, a wholly owned subsidiary of Numab. The transaction, valued at $1.25 billion in cash, includes the rights to NM26, a groundbreaking bi-specific antibody for treating atopic dermatitis. NM26, developed using Numab's proprietary MATCH technology, targets IL-4Rα and IL-31 to address the key aspects of atopic dermatitis. This innovative therapy exemplifies the cutting-edge advancements being made in bi-specific antibody drug development. This milestone marks our sixth consecutive billion-dollar+ exit within a year, following successful sales of Vectiv Bio, Inversago, Versanis, Aiolos Bio, and most recently, Mariana Oncology. Congratulations to the entire team at Forbion and Numab Therapeutics for this remarkable achievement! Read more using the following link: https://lnkd.in/edANY7ME #Biotechnology #Innovation #lifesciences #biotech Carlo Incerti

Forbion announces its participation in the $555M financing of Bicycle Therapeutics (BCYC). We are excited to support Kevin Lee and his incredible team as they build a leading biotechnology company rooted in outstanding innovation from Cambridge, U.K. Their work in delivering bicyclic peptide therapeutics to patients is truly groundbreaking. We continue to be committed to providing growth capital to scale the next generation of European leaders in our industry. This investment underscores our dedication to fostering cutting-edge advancements in biotechnology and improving patient outcomes. Read the official company release using the following link: https://lnkd.in/em6qYnDi #Biotechnology #Innovation #Investment #lifesciences #GrowthCapital #biotech Nanna Lüneborg Wouter Joustra Gilles van Tienderen, PhD Marc-Olivier Turgeon

Forbion portfolio company Noema Pharma AG, a clinical-stage biotech company targeting debilitating neuroscience-based disorders, today announced the first patient has been dosed in a Phase 2a open-label study evaluating the safety and efficacy of NOE-115, a broad-spectrum monoamine modulator, in #women with vasomotor symptoms (VMS, also referred to as “hot flashes”) as well as other symptoms such as weight gain, daytime #fatigue and cognitive difficulties due to #menopause. “The initiation of this study marks our fifth Phase 2 program to enter the clinic as we seek to develop transformative medicines for underserved conditions which are rooted in neuroscience,” said Ilise Lombardo, M.D., chief executive officer of Noema. “With over 2 million women in the U.S. entering menopause annually, there is significant medical need for a treatment option capable of addressing a broad constellation of symptoms that accompany the menopause transition, so that women are able to maintain their health and quality of life. These include vasomotor symptoms as well as weight gain, significant daytime fatigue and cognitive difficulties.” Read more using the following link: https://lnkd.in/eRy-p5DY #neuroscience #lifesciences #biotech Nanna Lüneborg Audrey Cacaly

Forbion announces that is has led a $65 million Series A financing of Progentos Therapeutics, a new biotech company focusing on treating degenerative diseases, with a lead program in multiple sclerosis. Forbion led the financing and is joined by Alta Partners, Mission BioCapital, Longwood Fund, and Dolby Family Ventures. Our own Dr. Dmitrij Hristodorov, General Partner, and Marc-Olivier Turgeon, Senior Associate, will join the Progentos Board of Directors. Progentos is tackling the critical unmet need for functional restoration in #CNS #diseases. Their lead program features a first-in-class small molecule to induce oligodendrocyte differentiation and remyelination of axons in MS. Read more in the link that follows: https://lnkd.in/eBfZSfen #lifesciences #venturecapital #biotech #forbion #seriesA

Congratulations to Forbion portfolio company Pheon Therapeutics (Pheon), a leading Antibody-Drug Conjugate (ADC) specialist developing next generation ADCs for a wide range of hard-to-treat cancers, on the completion of its $120m Series B financing to fund the development of its pipeline of differentiated ADCs. Read more using the following link: https://lnkd.in/enBFgJZ6 #lifesciences #biotech #seriesB #portfolionews Rogier Rooswinkel Marc-Olivier Turgeon

Forbion portfolio company enGene has added Paul Hastings and Forbion General Partner Wouter Joustra to its Board of Directors. Read the official release https://lnkd.in/eCe8YJGN #board #portfoliocompanynews #portfoliocompany #venturecapital #lifesciences #biotech

Forbion portfolio company AAVantgarde Bio (AAVantgarde), a clinical-stage, Italian-based international biotechnology company with two proprietary Adeno-Associated Viral (AAV) vector platforms for large gene delivery, today announced the presentation of the clinical trial design of the Company’s lead program in Usher 1B by the program’s Principal Investigator, Prof. Francesca Simonelli, at the 9th Annual Retinal Cell and Gene Therapy Innovation Summit, being held today in Seattle. Click on the following link to learn more: https://lnkd.in/eYWfJvgh Tim Lohoff, Ph.D. Dr. Dmitrij Hristodorov #research #lifesciences #biotech

Exciting news today for Forbion portfolio company Mariana Oncology. The company announces a landmark acquisition deal with Novartis worth $1 billion in cash upfront and up to $750 million in potential milestone payments. This strategic alliance merges Mariana Oncology's groundbreaking radiopharmaceutical pipeline and platform with Novartis' renowned clinical development and commercialization prowess. The synergy promises a new era of innovation and progress in the fight against cancer. Read more about Novartis' announcement and the acquisition details here: https://lnkd.in/g7CmCfbx This milestone follows a remarkable journey, including an oversubscribed $175 million Series B financing round in September 2023. Congratulations to everyone involved! Vanessa Carle Gilles van Tienderen, PhD Geert-Jan Mulder #MarianaOncology #Novartis #CancerInnovation #TransformingLives #lifesciences #biotech